logo
SPAR Shopper Survey: Consumers Focused on Product Availability, Tariffs and Tech

SPAR Shopper Survey: Consumers Focused on Product Availability, Tariffs and Tech

Business Wire2 days ago
AUBURN HILLS, Mich.--(BUSINESS WIRE)--A new consumer study conducted by SPAR Group, Inc. reveals that product availability is the single most important factor for shoppers when choosing to shop in-store, with 74% of respondents citing it as their top priority. At the same time, 73% of shoppers identify out-of-stocks as a leading barrier to the in-store experience, underscoring the critical need for retailers to maintain well-stocked shelves.
'The first rule of retail is that empty is always wrong. After decades of investment, inventory in-stock, plan-o-gram compliance and optimal replenishment remains elusive," said Mike Matacunas, President and CEO of SPAR Group.
Share
'The first rule of retail is that empty is always wrong. After decades of investment, inventory in-stock, plan-o-gram compliance and optimal replenishment remains elusive. Retailers and brands pay for data based on point-of-sale transactions as a proxy to monitoring inventory velocity, but this information is too late to make a difference. It's like driving your car looking in the rear-view mirror,' said Mike Matacunas, President and CEO of SPAR Group.
'This shopper study underscores the impact of distorted inventory – disappointed consumers, lost sales, lower margins. I am encouraged by the trend towards digital shelf innovation, but cautious based on the consumer's plans to navigate tariffs. We need to be bolder as an industry and embrace innovation. Great merchants test and learn.'
Technology and Innovation
The 2025 SPAR Consumer Survey highlights a growing interest in technology that enhances the in-store experience but also reveals consumer hesitancy toward certain innovations. 71% of shoppers are uncomfortable or unsure with the idea of roaming robots in stores, with women expressing more discomfort than men. Younger shoppers (ages 18-54) are more open to roaming robots than older demographics.
'Digital shelf monitoring is a growing market. Retailers are testing roving robots, stationery cameras and on-shelf moving field cameras. These promise to capture inventory information to improve plan-o-gram compliance, in-stock integrity and velocity data. As ex-retailers, we have sorted through the competitive solutions as a retailer and the winner is obvious. Consumers don't want technology to interfere with the shopping experience. Retailers don't want cameras on sticks every few feet. Moving field gondola-based cameras are the 'best mousetrap' for retailers,' continued Matacunas.
Economic Concerns and Shopper Behavior
Nearly half of shoppers are very concerned about tariffs, particularly regarding grocery prices. Many expect to seek out more coupons or sales, buy less overall or switch brands. Younger shoppers (ages 18–39) are especially likely to anticipate significant increases in expenses and express higher levels of concern.
'Consumers intend on reducing spend or switching brands as tariffs continue to roll out. The impact of tariffs further exacerbates consumer's frustration with inventory availability. Retailers and brands need to be more proactive investing in process and technology to improve availability and remain competitive,' said Matacunas.
Retailer Rankings
Walmart continues to lead in in-store experience and app helpfulness, especially among lower-income households. Target remains a distant second, while higher-income shoppers ($90K+) show a preference for Costco.
In-Store Shopping, Mobile Apps Remain Essential
Four of five shoppers prefer to purchase groceries in-store, driven by the ability to try products, discover new items and plan meals. Loyalty rewards and competitive prices are now equally valued as top benefits of retailer apps. Mobile apps are especially helpful for households earning $100K–$200K, while contactless checkout and buy-online-pickup-in-store options appeal to those in the $40K–$50K range.
Other Key Survey Findings
Positive In-Store Drivers: Speedy checkout, in-store promotions, self-checkout options and coupons are top contributors to a positive experience.
Challenges: Crowds and lack of staff remain significant pain points for shoppers.
Shopping Intentions: 61% of respondents expect to shop more in stores over the next six months.
Technology Preferences: Half of shoppers say downloadable coupons and self-checkout encourage them to shop in-store.
Data Sharing: Most shoppers are willing to share data with retailers, but about one in four now share only specific data for specific reasons, a notable increase from last year.
SPAR Group's Commitment
SPAR Group continues to support retailers and brands with solutions that address the evolving needs of today's shoppers. By leveraging advanced image capture, on-shelf availability technology and strategic partnerships, SPAR helps ensure products are available, promotions are effective and the in-store experience is seamless.
'As the retail landscape evolves, our mission remains the same: to help retailers and brands keep their customers happy, engaged and coming back,' said Matacunas. 'We're proud to be at the forefront of innovation, delivering the insights and services that drive real results for our partners and the shoppers they serve. If you want to learn more about our unique approach, please don't hesitate to reach out.'
Note to Editors: The complete results of the 2025 SPAR Consumer Survey are available HERE, or contact ron@rampr.com.
Methodology
During June 2025, SPAR Group fielded a survey through a third-party research firm with more than 1,000 consumers between the ages of 18 and 64. Respondents were screened to be the primary or secondary shopper in their households.
About SPAR Group, Inc.
SPAR Group is an innovative services company offering comprehensive merchandising, marketing and distribution solutions to retailers and brands. We provide the resources and analytics that improve brand experiences and transform retail spaces. We offer a unique combination of scale and flexibility with a passion for client results that separates us from the competition. For more information, please visit the SPAR Group's website at http://www.sparinc.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Business Wire

time2 hours ago

  • Business Wire

RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.

TransMedics Group, Inc. (TMDX): A Bull Case Theory
TransMedics Group, Inc. (TMDX): A Bull Case Theory

Yahoo

time3 hours ago

  • Yahoo

TransMedics Group, Inc. (TMDX): A Bull Case Theory

We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.

UnitedHealth Group Announces Changes to Leadership Team
UnitedHealth Group Announces Changes to Leadership Team

Yahoo

time5 hours ago

  • Yahoo

UnitedHealth Group Announces Changes to Leadership Team

July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store